Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: ERN, CCA, ACC

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation


BERGEN, Norway, Aug. 10, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, will be announcing its results for the second quarter 2020 on Tuesday 18 August 2020. A webcast presentation by BerGenBio's senior management team will take place at 10:00 am CET.

The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.

The second quarter report and presentation will be available on the Company's website in the Investors/Financial Reports section from 7:00 am CET the same day.

Contacts

Richard Godfrey
CEO
BerGenBio ASA
+47-917-86-304

Rune Skeie
CFO
BerGenBio ASA
[email protected]
+47-917-86-513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs,
Consilium Strategic Communications
[email protected]
+44-20-3709-5700

Media Relations in Norway

Jan Petter Stiff
Crux Advisers
[email protected]
+47-995-13-891

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive and therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer, leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic tests to identify those patient populations most likely to benefit from bemcentinib or tilvestamab: this is expected to facilitate more efficient registration trials and support a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).

For further information, please visit: www.bergenbio.com

This information was brought to you by Cision http://news.cision.com

 

SOURCE BerGenBio ASA


These press releases may also interest you

at 12:50
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)
Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 11, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired QuidelOrtho Corporation ("QuidelOrtho"...

at 11:40
Global Needle Coke Market Analysis and Forecasts, 2023-2024 and 2033: Evolution in UHP Graphite Electrode Applications and Vertical Integration of Needle Coke Business Fueling Opportunities - ResearchAndMarkets.com
The "Global Needle Coke Market: Focus on Application, Type, Grade, End Use, and Country-Level Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global needle coke market was valued at $3.05...

at 11:15
"e4life" is Present at Expomed Eurasia with its Innovative Device Able to Inactivate Flu and Covid Viruses With an Efficacy over 90%
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
NORA PHARMA RECEIVES HEALTH CANADA APPROVAL FOR NIOPEG®, A BIOSIMILAR OF NEULASTA®
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 09:35
Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research...

at 09:25
United States Telehealth Weight Loss Market Report 2024-2028: Impacts of COVID and GLP-1 Meds Featuring Weight Watchers, Noom, Ro.co, , AmWell, Amazon, Teladoc, Form Health, Form Health Among Others - ResearchAndMarkets.com
The "The U.S. Telehealth Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering The report includes in-depth analyses of: the scope of telehealth usage in the U.S., telehealth user demographics, pros and...

More news about Covid-19 virus...


News published on and distributed by: